MolecuLight, a point-of-care fluorescence imaging company, has closed a $11.7 million Series C financing round led by new investors Export Development Canada (EDC), Prosegur, and Azahar and including participation by existing investors.
The company's fluorescence imaging devices provide clinicians with real-time visualization of bacteria fluorescence in wounds. This allows for earlier detection and quantification, which leads to more effective treatment resulting in improved wound healing, MolecuLight said.
The new investment will fuel MolecuLight's expansion in the U.S., Canada, and the European Union across all care settings, including hospital outpatient, independent wound care clinics, podiatry practices, and long-term care centers.
